ID   S1-IR20
AC   CVCL_A9DE
DR   cancercelllines; CVCL_A9DE
DR   Wikidata; Q108821254
RX   PubMed=33692943;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; CPT-11).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0H88 ! S1
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=33692943; DOI=10.3389/fonc.2020.624954;
RA   Wu Z.-X., Yang Y.-Q., Zeng L.-L., Patel H., Bo L.-T., Lin L.-S.,
RA   Chen Z.-S.;
RT   "Establishment and characterization of an irinotecan-resistant human
RT   colon cancer cell line.";
RL   Front. Oncol. 10:624954.1-624954.8(2020).
//